Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myelomaOliver Van Oekelen, Samir Parekh, Sarita Agte et al.|Cancer Cell|2021Cited by 216
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phaseKomal Srivastava, Temima Yellin, Yuexing Chen et al.|Immunity|2024Cited by 134
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myelomaAdolfo Aleman, Christian Cognigni, Maria C. Bermúdez‐González et al.|Cancer Cell|2021Cited by 76
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patientsAdolfo Aleman, Samir Parekh, Oliver Van Oekelen et al.|Cancer Cell|2022Cited by 38